

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13. (Previously canceled)

Claim 14. (Currently amended): A composition comprising a divalent metal cation and a protease-resistant FLINT analog wherein said FLINT analog is resistant to proteolysis between position 218-219 of SEQ ID NO:1, or position 247-248 of SEQ ID NO:3.

Claim 15. (Original) A composition as in claim 14 wherein said cation is selected from the group consisting of  $Zn^{+2}$ ,  $Ca^{+2}$ ,  $Ni^{+2}$ ,  $Mn^{+2}$ ,  $Fe^{+2}$ ,  $Co^{+2}$ , and  $Cd^{+2}$ .

Claim 16. (Original) A composition of Claim 15, wherein the divalent metal cation is  $Zn^{+2}$ .

Claims 17-18 (Canceled)

Claim 19. (Currently amended): A ~~pharmaceutical~~ formulation comprising a composition of Claim ~~18~~ 14 in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.

Claim 20. (Original) A formulation of Claim 19, wherein the total cation concentration is about 0.001 to 5.0 mg/mL.

Claim 21. (Original) A formulation of Claim 20, wherein the total cation concentration is about 0.05 to 1.5 mg/mL.